Recent Articles By The Author
This is one of few homebuilder equities that did not have a big move up in 2020 and the stock is cheap.
T2 Biosystems and Tyme Technologies have both perked up of late after languishing for extended periods of time.
Oncology concern Exelixis and biopharma Ardelyx offer reasons to believe their shares should rise in the months ahead.
It's hard to find value in a picked-over market trading at all-time highs, which leaves this participant building his cash position.
The virtual work force, online shopping and a love of pets are not going to go away even after the coronavirus abates.
Look for a weaker dollar to perk up the energy sector, the exodus from big cities to continue, and gun and ammo sales to remain strong
I added to my stake in UniQure and initiated a new position in Lexicon Pharmaceuticals.